EyePoint, Inc. (EYPT)
2.99
-0.15
(-4.78%)
USD |
NASDAQ |
Oct 16, 16:00
3.09
+0.10
(+3.34%)
After-Hours: 20:00
EyePoint Research and Development Expense (Annual) : 221.04M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 221.04M |
| December 31, 2024 | 132.93M |
| December 31, 2023 | 64.36M |
| December 31, 2022 | 49.64M |
| December 31, 2021 | 28.50M |
| December 31, 2020 | 17.42M |
| December 31, 2019 | 15.37M |
| December 31, 2018 | 20.82M |
| June 30, 2017 | 14.41M |
| June 30, 2016 | 14.32M |
| Date | Value |
|---|---|
| June 30, 2015 | 11.37M |
| June 30, 2014 | 9.573M |
| June 30, 2013 | 7.005M |
| June 30, 2012 | 7.039M |
| June 30, 2011 | 6.864M |
| June 30, 2010 | 6.994M |
| June 30, 2009 | 8.007M |
| June 30, 2008 | 14.43M |
| June 30, 2007 | 21.06M |
| June 30, 2006 | 20.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ocular Therapeutix, Inc. | 197.10M |
| Corcept Therapeutics, Inc. | 254.91M |
| Eli Lilly & Co. | 13.34B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Nuvation Bio, Inc. | 115.11M |